E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial. Academic Article uri icon

Overview

publication date

  • October 9, 2023

Research

keywords

  • Neoplasms

Identity

PubMed Central ID

  • PMC10681888

Scopus Document Identifier

  • 85173969050

Digital Object Identifier (DOI)

  • 10.1038/s41375-023-02050-4

PubMed ID

  • 37814121

Additional Document Info

volume

  • 37

issue

  • 12